摘要
Background It is well known that there was a significant link between preprocedural blood glucose levels and short-term and long-term adverse outcomes in patients undergoing elective PCI. However, the role of preprocedural blood glucose levels as a predictor of adverse events in CKD patients who underwent PCI out of established diabetes has acute were coronary syndrome yet to be (ACS) identified. Methods In our study, we conducted a prospective study of 331 patients with CKD who underwent PCI out of established diabetes. Patients divided into two groups based on pre-procedural glucose levels (hypoglycemia 〈 7.0 mmol/L; hyperglycemia ≥ 7.0 mmol/L). All patients were followed up prospectively for major adverse cardiovascular events (MACEs) and mortality for 6 months. Results In our cohort, hyperglycemia patients reported a higher incidence of inhospital mortality than hypoglycemia patients (7.5% vs. 0%, P 〈 0.001). Hyperglycemia patients reported a significantly higher rate of 6-month MACEs (10% vs. 2.4%, P = 0.007), all cause mortality (7.5% vs. 1.6%, P = 0.015), and cardiovascular mortality (6.2%vs 1.6%, P = 0.041) compared with hypoglycemia patients with pre-procedural glucose levels 〈 7.0 mmol/L. Multivariate analysis disclosed that a pre-procedural glucose level ≥7.0 mmol/L was a significant independent predictor of MACEs (OR = 2.53, 95% CI 1.68-17.15, P = 0.004), all cause mortality(OR = 4.6, 95% CI 1.10-18.84, P = 0.036), and cardiovascular mortality(OR = 6.2, 95% CI 1.53-24.94, P = 0.011) at 6 months in patients after PCI. Conclusion The study suggested that pre-procedural glucose levels are associated with short-term cardiovascular outcome CKD patients who underwent PCI without established diabetes in the setting of ACS.
Background It is well known that there was a significant link between preprocedural blood glucose levels and short-term and long-term adverse outcomes in patients undergoing elective PCI. However, the role of preprocedural blood glucose levels as a predictor of adverse events in CKD patients who underwent PCI out of established diabetes has acute were coronary syndrome yet to be (ACS) identified. Methods In our study, we conducted a prospective study of 331 patients with CKD who underwent PCI out of established diabetes. Patients divided into two groups based on pre-procedural glucose levels (hypoglycemia 〈 7.0 mmol/L; hyperglycemia ≥ 7.0 mmol/L). All patients were followed up prospectively for major adverse cardiovascular events (MACEs) and mortality for 6 months. Results In our cohort, hyperglycemia patients reported a higher incidence of inhospital mortality than hypoglycemia patients (7.5% vs. 0%, P 〈 0.001). Hyperglycemia patients reported a significantly higher rate of 6-month MACEs (10% vs. 2.4%, P = 0.007), all cause mortality (7.5% vs. 1.6%, P = 0.015), and cardiovascular mortality (6.2%vs 1.6%, P = 0.041) compared with hypoglycemia patients with pre-procedural glucose levels 〈 7.0 mmol/L. Multivariate analysis disclosed that a pre-procedural glucose level ≥7.0 mmol/L was a significant independent predictor of MACEs (OR = 2.53, 95% CI 1.68-17.15, P = 0.004), all cause mortality(OR = 4.6, 95% CI 1.10-18.84, P = 0.036), and cardiovascular mortality(OR = 6.2, 95% CI 1.53-24.94, P = 0.011) at 6 months in patients after PCI. Conclusion The study suggested that pre-procedural glucose levels are associated with short-term cardiovascular outcome CKD patients who underwent PCI without established diabetes in the setting of ACS.